Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma

Chinese Journal of Cancer Research

Volumn 25, Issue 2, 2013, Pages 206-211

  Cai, Lin Bo ^a   Li, Juan ^a   Lai, Ming Yao ^a   Shan, Chang Guo ^a   Lian, Zong De ^a   Hong, Wei Ping ^a   Zhen, Jun Jie ^a   Zhou, Qing ^a   Wang, Li Chao ^a  

^a Guangdong 999 Brain Hospital   (China)

Author keywords

Bevacizumab; Recurrent malignant glioma

Indexed keywords

BEVACIZUMAB; CISPLATIN; CORTICOSTEROID; ETOPOSIDE; NIMUSTINE; TEMOZOLOMIDE; TENIPOSIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHILD; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; DISEASE COURSE; DOSE DENSIFICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEINURIA; RADIATION DOSE DISTRIBUTION; RECURRENT CANCER; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCHOOL CHILD; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84883749172     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2013.03.10     Document Type: Article

References (19)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
2. Lamborn KR, Yung WK, Chang SM, et al. Progression- free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10:162-70.
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
4. Cui B, Johnson SP, Bullock N, et al. Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells. J Biomed Res 2010;24:424-35.
5. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007;9:29-38. (Pubitemid 46543486)
6. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
7. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9. (Pubitemid 350086473)
8. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
9. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
10. Kyritsis AP, Levin VA. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 2011;67:971-83.
11. Li P, Lu X, Wang Y, et al. MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells. J Biomed Res 2010;24:436-43.
12. Liang C, Guo S, Yang L. All-trans retinoic acid upregulates VEGF expression in glioma cells in vitro. J Biomed Res 2013; 27:51-5.
13. Reardon DA, Desjardins A, Rich JN, et al. The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol 2008;9:1-22.
14. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-5.
15. Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010;12:26-33.
16. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80. (Pubitemid 20195640)
17. Nagane M, Nishikawa R, Narita Y, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 2012;42:887-95.
18. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200-6.
19. Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 2009;11:550-5.